Aortic dose constraints when reirradiating thoracic tumors
- PMID: 23453540
- PMCID: PMC3921976
- DOI: 10.1016/j.radonc.2013.02.002
Aortic dose constraints when reirradiating thoracic tumors
Abstract
Background and purpose: Improved radiation delivery and planning has allowed, in some instances, for the retreatment of thoracic tumors. We investigated the dose limits of the aorta wherein grade 5 aortic toxicity was observed after reirradiation of lung tumors.
Material and methods: In a retrospective analysis, 35 patients were identified, between 1993 and 2008, who received two rounds of external beam irradiation that included the aorta in the radiation fields of both the initial and retreatment plans. We determined the maximum cumulative dose to 1 cm(3) of the aorta (the composite dose) for each patient, normalized these doses to 1.8 Gy/fraction, and corrected them for long-term tissue recovery between treatments (NIDR).
Results: The median time interval between treatments was 30 months (range, 1-185 months). The median follow-up of patients alive at analysis was 42 months (range, 14-70 months). Two of the 35 patients (6%) were identified as having grade 5 aortic toxicities. There was a 25% rate of grade 5 aortic toxicity for patients receiving composite doses ≥120.0 Gy (vs. 0% for patients receiving <120.0 Gy) (P=0.047).
Conclusions: Grade 5 aortic toxicities were observed with composite doses ≥120.0 Gy (NIDR ≥90.0 Gy) to 1cm(3) of the aorta.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):808-15. doi: 10.1016/j.ijrobp.2015.12.007. Epub 2015 Dec 17. Int J Radiat Oncol Biol Phys. 2016. PMID: 26831903
-
Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region.Breast Cancer Res Treat. 2009 Mar;114(2):307-13. doi: 10.1007/s10549-008-9995-3. Epub 2008 Apr 4. Breast Cancer Res Treat. 2009. PMID: 18389365
-
High-dose-rate (HDR) or pulsed-dose-rate (PDR) perioperative interstitial intensity-modulated brachytherapy (IMBT) for local recurrences of previously irradiated breast or thoracic wall following breast cancer.Strahlenther Onkol. 2006 Feb;182(2):102-7. doi: 10.1007/s00066-006-1496-x. Strahlenther Onkol. 2006. PMID: 16447017
-
How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):897-913. doi: 10.1016/s0360-3016(97)00854-7. Int J Radiat Oncol Biol Phys. 1998. PMID: 9531376 Review.
-
Chemo-reirradiation in persistent/recurrent head and neck cancers.Jpn J Clin Oncol. 2004 Feb;34(2):61-8. doi: 10.1093/jjco/hyh017. Jpn J Clin Oncol. 2004. PMID: 15067097 Review.
Cited by
-
Comparative analysis of dose calculation algorithms for CyberKnife-based stereotactic radiotherapy in lung cancer.Front Oncol. 2023 Oct 2;13:1215976. doi: 10.3389/fonc.2023.1215976. eCollection 2023. Front Oncol. 2023. PMID: 37849803 Free PMC article.
-
Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era.Front Oncol. 2023 Jan 17;12:1074675. doi: 10.3389/fonc.2022.1074675. eCollection 2022. Front Oncol. 2023. PMID: 36733369 Free PMC article.
-
Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis.JHEP Rep. 2022 Sep 22;5(1):100594. doi: 10.1016/j.jhepr.2022.100594. eCollection 2023 Jan. JHEP Rep. 2022. PMID: 36561128 Free PMC article.
-
Profiling mRNA, miRNA and lncRNA expression changes in endothelial cells in response to increasing doses of ionizing radiation.Sci Rep. 2022 Nov 19;12(1):19941. doi: 10.1038/s41598-022-24051-6. Sci Rep. 2022. PMID: 36402833 Free PMC article.
-
The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study.Front Oncol. 2022 Oct 14;12:921473. doi: 10.3389/fonc.2022.921473. eCollection 2022. Front Oncol. 2022. PMID: 36313653 Free PMC article.
References
-
- Kramer GW, Gans S, Ullmann E, et al. Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment? Int J Radiat Oncol Biol Phys. 2004;58(5):1388–1393. - PubMed
-
- Baumann P, Nyman J, Hoyer M, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88(3):359–367. - PubMed
-
- Creach KM, Bradley JD, Mahasittiwat P, et al. Stereotactic body radiation therapy in the treatment of multiple primary lung cancers. Radiother Oncol. 2012;104(1):19–22. - PubMed
-
- Jeremic B, Videtic GM. Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys. 2011;80:969–977. - PubMed
-
- van Baardwijk A, Tome WA, van Elmpt W, et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol. 2012;105(2):145–149. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
